Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use

Abstract

Human immunodeficiency virus (HIV) patients have more aggressive presentation of colorectal cancer (CRC) and less favourable outcome. Bevacizumab is an antiangiogenic agent that has emerged as a major drug for metastatic CRC. However, few data are available on the safety of bevacizumab in HIV patients. In the light of a case study, we briefly draw intention on how angiogenesis inhibitors could interact with antiviral tri-therapy.

Keywords:

• AIDS
• Bevacizumab
• Targeted therapies
• Toxicity